Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.

Wilding, J P H; Bain, S C

Wilding, J P H; Bain, S C.

Affiliation

Wilding JP; Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK.
Bain SC; Institute of Life Science, Swansea University, Swansea, UK.

Diabet Med ; 33(7): 864-76, 2016 07.

Article in En | MEDLINE | ID: mdl-26525806

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use; Hypoglycemic Agents/therapeutic use; Incretins/therapeutic use; Insulin, Long-Acting/therapeutic use; Liraglutide/therapeutic use; Blood Glucose/metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2/metabolism; Drug Combinations; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor/agonists; Glycated Hemoglobin/metabolism; Humans; Hypoglycemia/chemically induced; Insulin/therapeutic use; Insulin Glargine/therapeutic use; Peptides/therapeutic use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin, Long-Acting / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Incretins / Liraglutide / Hypoglycemic Agents Limits: Humans Language: En Journal: Diabet Med Year: 2016 Document type: Article

Fulltext

XML

PubMed Links

Search on Google